search tools

08.03.2016 – Media Release: The Financial Year 2015 (Swiss Finance & Property Investment AG)

Edit Public Technologies 08 Mar 2016
(Source. Swiss Finance & Property Investment AG) Microsoft Word - SFPI_MM_GB15_EN.docx. Media Release. for immediate release 8 March 2016. The Financial Year 2015. Substantial 24.8% increase of net profits excluding revaluation effects to CHF 12.6 Mio. or CHF 5.05 per share. Marked increase by 13.2% of operating income before revaluation to CHF 21.7 Mio ... Furthermore, by 30 October 2015, the property in Liestal was sold as well ... Outlook 2016....

DT MedTech Acquires Worldwide Ownership of Hintermann Series of Lower Extremity Replacement and Revision Medical Devices

Edit PR Newswire 03 Mar 2016
BALTIMORE, March 3, 2016 /PRNewswire/ -- DT MedTech, LLC (DTMT) announced today that it has successfully completed the acquisition of ownership of the Hintermann Series lower extremity device product line ... Dr ... DT MedTech, LLC maintains offices in Baltimore, Maryland; Salt Lake City, Utah; Saint-Louis, France; and Liestal, Switzerland, and is a stand alone limited liability company owned by Data Trace Partners III, LLC and ROBEAMA GmbH....

01.Mar.2016 - SWISS welcomes Canton Baselland aboard (Swiss International Air Lines Ltd)

Edit Public Technologies 02 Mar 2016
(Source. Swiss International Air Lines Ltd). Zurich Airport, 1 March 2016 ... SWISS will also be celebrating the 'Banntag' custom in Liestal (Baselland) in mid-April under its 'SWISS Traditions' banner ... There's no menu at the Schlüssel ... a refreshing Riesling-Sylvaner and an elegant Pinot Noir ... Ever year around Ascension Day the people of Liestal process around the town's limits with banners, pipes and drums to check the boundary stones....

January 27, 2016: Santhera Reports Preliminary Key Financial Figures for 2015 (Santhera Pharmaceuticals Holding AG) ...

Edit Public Technologies 27 Jan 2016
(Source. Santhera Pharmaceuticals Holding AG). Liestal, Switzerland, January 27, 2016 - Santhera Pharmaceuticals (SIX. SANN) announces preliminary, unaudited key financial figures for 2015. The Company reports net revenues of CHF 4.3 million from sales of its lead product Raxone for the treatment of Leber's hereditary optic neuropathy (LHON). Commercial roll-out for Raxone for the treatment of LHON in the EU is well on track ... # # # ... (noodl....

10.12.2015 – Press Release -SFPI- Basel - Securing land (Swiss Finance & Property Investment AG) ...

Edit Public Technologies 11 Dec 2015
(Source. Swiss Finance & Property Investment AG) Brief an die Aktionäre der Swiss Finance & Property Investment AG. Press Release of Swiss Finance & Property Investment AG. Zurich, 10 December 2015. Securing attractive land in Basel ... The plot is adjacent to the St ... Furthermore, consistent with the portfolio optimization strategy, as of 30 October 2015 the property Mühlegasse 2 in Liestal was sold above current market valuation. Contact.....

December 02, 2015: Santhera Completed Share Placement and Raised CHF 54.8 Million (Santhera Pharmaceuticals Holding ...

Edit Public Technologies 02 Dec 2015
(Source. Santhera Pharmaceuticals Holding AG). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN. Liestal, Switzerland, December 2, 2015 -Santhera Pharmaceuticals (SIX. SANN) successfully completed the placement of shares which was announced yesterday ... About Santhera. Santhera Pharmaceuticals (SIX ... Disclaimer / Forward-looking statements ... Securities Act....

02. Dezember 2015: Santhera schliesst Aktienplatzierung mit einem Erlös von CHF 54.8 Millionen ab (Santhera ...

Edit Public Technologies 02 Dec 2015
(Source. Santhera Pharmaceuticals Holding AG). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN. Liestal, Schweiz, 2. Dezember 2015 -Santhera Pharmaceuticals (SIX. SANN) hat die gestern angekündigte Aktienplatzierung erfolgreich abgeschlossen ... Dezember 2015 veräussert ... Der Handel der neuen Aktien an der SIX Swiss Exchange wird voraussichtlich am 3....

December 01, 2015: Santhera Launches Placement of up to 500,000 New Shares Through an Accelerated ...

Edit Public Technologies 01 Dec 2015
(Source. Santhera Pharmaceuticals Holding AG). NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA OR JAPAN. Liestal, Switzerland, December 1 2015 - Santhera Pharmaceuticals (SIX. SANN) announces that it plans to place up to 500,000 new shares from its authorized capital, representing 8.8% of the Company's currently outstanding shares ... About Santhera ... # # #....

November 11, 2015: Santhera Reports New Data and Updates on Regulatory Filings for Raxone® (idebenone) ...

Edit Public Technologies 11 Nov 2015
(Source. Santhera Pharmaceuticals Holding AG). Liestal, Switzerland, November 11, 2015 -Santhera Pharmaceuticals (SIX. SANN) announces that it has now completed comparative analyses of the respiratory outcomes for patients in its successful Phase III DELOS trial with data from a natural history DMD patient cohort collected by the Cooperative International Neuromuscular Research Group (CINRG) ... ... 0.131, 0.843; p = 0.020) and 0.271 (95% CI....

October 22, 2015: Santhera and Parent Project Muscular Dystrophy (PPMD) Announce Results of Benefit / ...

Edit Public Technologies 22 Oct 2015
(Source. Santhera Pharmaceuticals Holding AG). Liestal, Switzerland, October 22, 2015 - Santhera Pharmaceuticals (SIX. SANN) and Parent Project Muscular Dystrophy (PPMD), the leading U.S. advocacy organization working to end Duchenne Muscular Dystrophy (DMD), announce the results of a benefit/risk survey in patients DMD and parents of individuals with DMD ... About the PPMD Benefit/Risk Survey Study ... About Santhera ... # # #. distributed by....

October 01, 2015: Santhera launches Raxone® in its first EU market (Santhera Pharmaceuticals Holding AG) ...

Edit Public Technologies 01 Oct 2015
(Source. Santhera Pharmaceuticals Holding AG). Liestal, Switzerland, October 1, 2015 - Santhera Pharmaceuticals (SIX. SANN) announces that it is today launching Raxone® for the treatment of Leber's Hereditary Optic Neuropathy (LHON) in Germany, its first and largest EU market. LHON is a rare inherited mitochondrial disease that usually leads rapidly to profound and permanent blindness ... About Santhera. Santhera Pharmaceuticals (SIX ... # # #....

September 15, 2015: Santhera CEO Exercises Options and Increases his Shareholding in Santhera (Santhera Pharmaceuticals ...

Edit Public Technologies 15 Sep 2015
(Source. Santhera Pharmaceuticals Holding AG). Liestal, Switzerland, September 15, 2015 - Santhera Pharmaceuticals (SIX. SANN) announces that Thomas Meier, PhD, Chief Executive Officer of Santhera, has exercised all his vested options to acquire 104'394 registered shares of the Company. Of these, 70'000 shares were simultaneously sold to cover transaction and related tax expenses. After the transaction, Dr ... About Santhera. ... (noodl....

September 09, 2015: Santhera Receives European Marketing Authorization for Raxone® in Leber's Hereditary Optic Neuropathy ...

Edit Public Technologies 09 Sep 2015
(Source. Santhera Pharmaceuticals Holding AG). First Approved Treatment for LHON and First Approved Treatment for a Mitochondrial Disease Liestal, Switzerland, September 9, 2015 - Santhera Pharmaceuticals (SIX ... This rare condition is an inherited mitochondrial disease which if untreated usually leads to rapid, profound and permanent blindness in otherwise healthy patients ... Most will remain permanently blind if untreated." ... (noodl....
×
×
×
×